Literature DB >> 22174555

AG490: an inhibitor of hepcidin expression in vivo.

Shu-Ping Zhang, Zhe Wang, Li-Xin Wang, Si-Jin Liu.   

Abstract

A liver-produced hormone, hepcidin, appears to be the key player in iron metabolism. The overexpression of hepcidin is the underlying cause of anemia of inflammation. The identification of compounds inhibiting hepcidin expression could ameliorate anemia associated with inflammation. In the current study, we have demonstrated for the first time that AG490 significantly abolishes hepcidin expression in mice. Our work represents a novel approach to suppress hepcidin expression for treatment of anemia of inflammation and anemias occurring under other conditions.

Entities:  

Keywords:  AG490; Anemia; Hepcidin; Inflammation

Mesh:

Substances:

Year:  2011        PMID: 22174555      PMCID: PMC3236577          DOI: 10.3748/wjg.v17.i45.5032

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  12 in total

Review 1.  Iron homeostasis and the inflammatory response.

Authors:  Marianne Wessling-Resnick
Journal:  Annu Rev Nutr       Date:  2010-08-21       Impact factor: 11.848

2.  Heparin: a potent inhibitor of hepcidin expression in vitro and in vivo.

Authors:  Maura Poli; Domenico Girelli; Natascia Campostrini; Federica Maccarinelli; Dario Finazzi; Sara Luscieti; Antonella Nai; Paolo Arosio
Journal:  Blood       Date:  2010-11-12       Impact factor: 22.113

3.  Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor.

Authors:  N Meydan; T Grunberger; H Dadi; M Shahar; E Arpaia; Z Lapidot; J S Leeder; M Freedman; A Cohen; A Gazit; A Levitzki; C M Roifman
Journal:  Nature       Date:  1996-02-15       Impact factor: 49.962

Review 4.  The role of hepcidin in iron metabolism.

Authors:  Elizabeta Nemeth; Tomas Ganz
Journal:  Acta Haematol       Date:  2009-11-10       Impact factor: 2.195

5.  Inhibition of rho-associated kinase signaling prevents breast cancer metastasis to human bone.

Authors:  Sijin Liu; Robert H Goldstein; Ellen M Scepansky; Michael Rosenblatt
Journal:  Cancer Res       Date:  2009-11-03       Impact factor: 12.701

6.  Deficiency of heme-regulated eIF2alpha kinase decreases hepcidin expression and splenic iron in HFE-/- mice.

Authors:  Sijin Liu; Rajasekhar N V S Suragani; Anping Han; Wanting Zhao; Nancy C Andrews; Jane-Jane Chen
Journal:  Haematologica       Date:  2008-03-26       Impact factor: 9.941

7.  WP1066, a novel JAK2 inhibitor, suppresses proliferation and induces apoptosis in erythroid human cells carrying the JAK2 V617F mutation.

Authors:  Srdan Verstovsek; Taghi Manshouri; Alfonso Quintás-Cardama; David Harris; Jorge Cortes; Francis J Giles; Hagop Kantarjian; Waldemar Priebe; Zeev Estrov
Journal:  Clin Cancer Res       Date:  2008-02-01       Impact factor: 12.531

8.  The function of heme-regulated eIF2alpha kinase in murine iron homeostasis and macrophage maturation.

Authors:  Sijin Liu; Rajasekhar N V S Suragani; Fudi Wang; Anping Han; Wanting Zhao; Nancy C Andrews; Jane-Jane Chen
Journal:  J Clin Invest       Date:  2007-11       Impact factor: 14.808

9.  WP1066 disrupts Janus kinase-2 and induces caspase-dependent apoptosis in acute myelogenous leukemia cells.

Authors:  Alessandra Ferrajoli; Stefan Faderl; Quin Van; Patricia Koch; David Harris; Zhiming Liu; Inbal Hazan-Halevy; Yongtao Wang; Hagop M Kantarjian; Waldemar Priebe; Zeev Estrov
Journal:  Cancer Res       Date:  2007-12-01       Impact factor: 12.701

10.  Natural and synthetic STAT3 inhibitors reduce hepcidin expression in differentiated mouse hepatocytes expressing the active phosphorylated STAT3 form.

Authors:  Nadia Fatih; Emilie Camberlein; Marie Laure Island; Anne Corlu; Emmanuelle Abgueguen; Lénaïck Détivaud; Patricia Leroyer; Pierre Brissot; Olivier Loréal
Journal:  J Mol Med (Berl)       Date:  2010-02-19       Impact factor: 4.599

View more
  13 in total

Review 1.  Modulation of hepcidin to treat iron deregulation: potential clinical applications.

Authors:  Nicole L Blanchette; David H Manz; Frank M Torti; Suzy V Torti
Journal:  Expert Rev Hematol       Date:  2015-12-15       Impact factor: 2.929

2.  JAK2/STAT3 Signaling Pathway and Klotho Gene in Cadmium-induced Neurotoxicity In Vitro and In Vivo.

Authors:  Shuzhen Liu; Dongmei Yu; Peng Wei; Jiansheng Cai; Min Xu; Haoyu He; Xu Tang; Chuntao Nong; Yi Wei; Xia Xu; Xiaoting Mo; Zhiyong Zhang; Jian Qin
Journal:  Biol Trace Elem Res       Date:  2022-09-27       Impact factor: 4.081

3.  Iron regulation by hepcidin.

Authors:  Ningning Zhao; An-Sheng Zhang; Caroline A Enns
Journal:  J Clin Invest       Date:  2013-06-03       Impact factor: 14.808

Review 4.  Manipulation of the hepcidin pathway for therapeutic purposes.

Authors:  Eileen Fung; Elizabeta Nemeth
Journal:  Haematologica       Date:  2013-11       Impact factor: 9.941

Review 5.  Hepcidin: A Promising Therapeutic Target for Iron Disorders: A Systematic Review.

Authors:  Jing Liu; Bingbing Sun; Huijun Yin; Sijin Liu
Journal:  Medicine (Baltimore)       Date:  2016-04       Impact factor: 1.889

Review 6.  Antimicrobial Activity of Mesenchymal Stem Cells: Current Status and New Perspectives of Antimicrobial Peptide-Based Therapies.

Authors:  Francisca Alcayaga-Miranda; Jimena Cuenca; Maroun Khoury
Journal:  Front Immunol       Date:  2017-03-30       Impact factor: 7.561

Review 7.  Targeting iron metabolism in drug discovery and delivery.

Authors:  Bart J Crielaard; Twan Lammers; Stefano Rivella
Journal:  Nat Rev Drug Discov       Date:  2017-02-03       Impact factor: 84.694

Review 8.  Hepcidin antagonists for potential treatments of disorders with hepcidin excess.

Authors:  Maura Poli; Michela Asperti; Paola Ruzzenenti; Maria Regoni; Paolo Arosio
Journal:  Front Pharmacol       Date:  2014-04-28       Impact factor: 5.810

Review 9.  Hepcidin and sports anemia.

Authors:  Wei-Na Kong; Guofen Gao; Yan-Zhong Chang
Journal:  Cell Biosci       Date:  2014-04-14       Impact factor: 7.133

Review 10.  Pharmacological Targeting of the Hepcidin/Ferroportin Axis.

Authors:  Giada Sebastiani; Nicole Wilkinson; Kostas Pantopoulos
Journal:  Front Pharmacol       Date:  2016-06-21       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.